Emily Curran1, Sonali M Smith. 1. Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, Illinois, USA.
Abstract
PURPOSE OF REVIEW: The phosphoinositide 3-kinase (PI3K) pathway, with downstream targets including Akt and mammalian target of rapamycin, has been implicated in numerous human cancers, including hematologic malignancies and lymphomas. The development and refinement of PI3K inhibitors directed toward this pathway show promising clinical efficacy. This review will discuss the emerging body of clinical data in lymphoid malignancies and present future directions for research utilizing these inhibitors. RECENT FINDINGS: The PI3Kδ inhibitor, idelalisib, has been most widely studied in lymphoma, and has shown promising results both as a single agent and in combination with other therapies. IPI-145, a dual inhibitor of PI3Kδ and PI3Kγ, has also shown efficacy and several clinical trials are underway. Other PI3K inhibitors are in active development, with several entering early phase clinical trials. SUMMARY: The PI3K pathway appears to be important in lymphoma and targeting this pathway shows promising clinical efficacy.
PURPOSE OF REVIEW: The phosphoinositide 3-kinase (PI3K) pathway, with downstream targets including Akt and mammalian target of rapamycin, has been implicated in numerous human cancers, including hematologic malignancies and lymphomas. The development and refinement of PI3K inhibitors directed toward this pathway show promising clinical efficacy. This review will discuss the emerging body of clinical data in lymphoid malignancies and present future directions for research utilizing these inhibitors. RECENT FINDINGS: The PI3Kδ inhibitor, idelalisib, has been most widely studied in lymphoma, and has shown promising results both as a single agent and in combination with other therapies. IPI-145, a dual inhibitor of PI3Kδ and PI3Kγ, has also shown efficacy and several clinical trials are underway. Other PI3K inhibitors are in active development, with several entering early phase clinical trials. SUMMARY: The PI3K pathway appears to be important in lymphoma and targeting this pathway shows promising clinical efficacy.
Authors: Yardena Samuels; Zhenghe Wang; Alberto Bardelli; Natalie Silliman; Janine Ptak; Steve Szabo; Hai Yan; Adi Gazdar; Steven M Powell; Gregory J Riggins; James K V Willson; Sanford Markowitz; Kenneth W Kinzler; Bert Vogelstein; Victor E Velculescu Journal: Science Date: 2004-03-11 Impact factor: 47.728
Authors: D Chantry; A Vojtek; A Kashishian; D A Holtzman; C Wood; P W Gray; J A Cooper; M F Hoekstra Journal: J Biol Chem Date: 1997-08-01 Impact factor: 5.157
Authors: Brad S Kahl; Stephen E Spurgeon; Richard R Furman; Ian W Flinn; Steven E Coutre; Jennifer R Brown; Don M Benson; John C Byrd; Sissy Peterman; Yoonjin Cho; Albert Yu; Wayne R Godfrey; Nina D Wagner-Johnston Journal: Blood Date: 2014-03-10 Impact factor: 22.113
Authors: B Vanhaesebroeck; M J Welham; K Kotani; R Stein; P H Warne; M J Zvelebil; K Higashi; S Volinia; J Downward; M D Waterfield Journal: Proc Natl Acad Sci U S A Date: 1997-04-29 Impact factor: 11.205
Authors: Klaus Okkenhaug; Antonio Bilancio; Géraldine Farjot; Helen Priddle; Sara Sancho; Emma Peskett; Wayne Pearce; Stephen E Meek; Ashreena Salpekar; Michael D Waterfield; Andrew J H Smith; Bart Vanhaesebroeck Journal: Science Date: 2002-07-18 Impact factor: 47.728
Authors: Tycel J Phillips; Andres Forero-Torres; Taimur Sher; Catherine S Diefenbach; Patrick Johnston; Moshe Talpaz; Jennifer Pulini; Li Zhou; Peggy Scherle; Xuejun Chen; Paul M Barr Journal: Blood Date: 2018-04-25 Impact factor: 22.113
Authors: Jia Wang; Grace Qun Gong; Yan Zhou; Woo-Jeong Lee; Christina Maree Buchanan; William Alexander Denny; Gordon William Rewcastle; Jackie Diane Kendall; James Michael Jeremy Dickson; Jack Urquhart Flanagan; Peter Robin Shepherd; De-Hua Yang; Ming-Wei Wang Journal: Acta Pharmacol Sin Date: 2018-07-10 Impact factor: 6.150
Authors: Hongyan Wu; Xinyi Tang; Hyo Jin Kim; Shahrzad Jalali; Joshua C Pritchett; Jose C Villasboas; Anne J Novak; Zhi-Zhang Yang; Stephen M Ansell Journal: J Immunother Cancer Date: 2021-07 Impact factor: 13.751
Authors: Ajay Major; Justin Kline; Theodore G Karrison; Paul A S Fishkin; Amy S Kimball; Adam M Petrich; Sreenivasa Nattam; Krishna Rao; Bethany G Sleckman; Kenneth Cohen; Koen van Besien; Aaron P Rapoport; Sonali M Smith Journal: Haematologica Date: 2022-07-01 Impact factor: 11.047